

# Nurosene Health Inc. Announces Change to its Board of Directors

TORONTO, Feb. 4, 2022 /CNW/ - Nurosene Health Inc. ("**Nurosene**" or the "**Company**") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on building a generation of better brains, announces that Kirstine Stewart has resigned as a Director of the Company due to personal reasons.

The Company would like to thank Ms Stewart for her contributions to Nurosene over the last twelve months and wishes her the best in her future endeavours. Kirstine was vital in connecting Nurosene with leading Mental Wellness Organizations and will continue to support Nurosene's mission from the sidelines.

"Kirstine has been an invaluable part of the Company's growth to date. Everyone associated with the Company would like to thank Kirstine and wish her all the best in her future endeavours," said Kevin Taylor, Chairman Nurosene.

## About Nurosene

Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.

For more information, visit [www.nurosene.com](http://www.nurosene.com).

## Forward-Looking Statements


This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and

filed with the applicable Canadian securities regulatory authorities on SEDAR at [www.sedar.com](http://www.sedar.com). The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

 View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/February2022/04/c1357.html>

%SEDAR: 00050449E

**For further information:** Blake Sing, Chief Financial Officer, [investors@nurosene.com](mailto:investors@nurosene.com), (416) 859 8838

CO: Nurosene Health Inc.

CNW 18:03e 04-FEB-22